Analyst Price Target is $6.38
▲ +183.33% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Corvus Pharmaceuticals in the last 3 months. The average price target is $6.38, with a high forecast of $8.00 and a low forecast of $3.50. The average price target represents a 183.33% upside from the last price of $2.25.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Corvus Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.